title: Troglitazone reduces plasma levels of tumour necrosis factor-alpha in obese patients with type 2 diabetes.
abstract: We evaluated the effect of troglitazone (given orally 400 mg/day) on glucose intolerance and on the plasma levels of tumour necrosis factor-alpha (TNF-alpha) in 12 obese patients with type 2 diabetes for 12 weeks. Troglitazone significantly decreased fasting plasma glucose, serum C-peptide, serum insulin and HbA1c levels. Plasma levels of TNF-alpha were significantly reduced by troglitazone administered for 8 and 12 weeks. Troglitazone administration significantly improved insulin resistance, but did not affect pancreatic beta-cell function as evaluated by the homeostasis model assessment (HOMA). In the present study, we reported for the first time that troglitazone administration significantly reduces plasma levels of TNF-alpha in obese patients with type 2 diabetes.
authors.affiliation: Third Department of Internal Medicine, Mie University School of Medicine, Tsu, Japan. katuki-a-@clin.medic.mie-u.ac.jp
authors.forename: A
authors.initials: A
authors.lastname: Katsuki
authors.forename: Y
authors.initials: Y
authors.lastname: Sumida
authors.forename: K
authors.initials: K
authors.lastname: Murata
authors.forename: M
authors.initials: M
authors.lastname: Furuta
authors.forename: R
authors.initials: R
authors.lastname: Araki-Sasaki
authors.forename: K
authors.initials: K
authors.lastname: Tsuchihashi
authors.forename: Y
authors.initials: Y
authors.lastname: Hori
authors.forename: Y
authors.initials: Y
authors.lastname: Yano
authors.forename: E C
authors.initials: EC
authors.lastname: Gabazza
authors.forename: Y
authors.initials: Y
authors.lastname: Adachi
mesh_terms: D001786:Blood Glucose / Q000378:metabolism; D002096:C-Peptide / Q000097:blood; D002839:Chromans / Q000494:pharmacology / Q000627:therapeutic use*; D003920:Diabetes Mellitus / Q000097:blood / Q000188:drug therapy*; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy*; D006442:Glycated Hemoglobin / Q000032:analysis; D006801:Humans; D007004:Hypoglycemic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D007328:Insulin / Q000097:blood; D007333:Insulin Resistance; D009765:Obesity; D013844:Thiazoles / Q000494:pharmacology / Q000627:therapeutic use*; D045162:Thiazolidinediones; D000077288:Troglitazone; D014409:Tumor Necrosis Factor-alpha / Q000032:analysis* / Q000187:drug effects
chemical_list: D001786:Blood Glucose; D002096:C-Peptide; D002839:Chromans; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D007328:Insulin; D013844:Thiazoles; D045162:Thiazolidinediones; D000077288:Troglitazone; D014409:Tumor Necrosis Factor-alpha